Literature DB >> 165022

Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease.

G Dahlén, K Berg, T Gillnäs, C Ericson.   

Abstract

A strong, positive association (P smaller than 0.0001) was found between the presence in serum of pre-beta1-lipoprotein upon electrophoresis in 0.5% agarose and the Lp(a+) phenotype in a series of 103 males aged 50-52 years participating in a health control study and in a series of 58 patients with sustained myocardial infarction. Both lipiprotein phenomena were more prevalent in the 58 patients than in the 103 presumably healthy males. The lack of any significant difference between total cholesterol values in the patients and the controls, despite the higher frequency of phenotype Lp(a+) in the former group, argues against the suggestion by Walton et al. (1974) that the increased Lp(a+) frequency in patients with coronary artery disease may be caused by a general increase in the concentration of low density lipoproteins (LDL).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165022     DOI: 10.1111/j.1399-0004.1975.tb00338.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  13 in total

1.  Studies on the late-pre-beta-lipoprotein of human serum.

Authors:  I C Ononogbu
Journal:  Experientia       Date:  1979-09-15

Review 2.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 3.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

4.  Genetic variation in serum low density lipoproteins and lipid levels in man.

Authors:  K Berg; C Hames; G Dahlén; M H Frick; I Krishan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

5.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.

Authors:  C Sandholzer; E Boerwinkle; N Saha; M C Tong; G Utermann
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

6.  Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin.

Authors:  C D Byrne; T W Wang; C N Hales
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

7.  Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.

Authors:  D L Eaton; G M Fless; W J Kohr; J W McLean; Q T Xu; C G Miller; R M Lawn; A M Scanu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

Authors:  F Pazzucconi; L Mannucci; L Mussoni; G Gianfranceschi; P Maderna; P Werba; G Franceschini; C R Sirtori; E Tremoli
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 9.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

Review 10.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.